Eisai Newsroom - Newsroom

NEWSROOM

An online resource for members of the media and the investment community.

SUBSCRIBE TO EMAIL ALERTS

VIEW OUR LATEST RELEASES

Sep 14, 2024

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Sep 4, 2024

Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024, Including First Interim Analysis Results from the Phase 3 LEAP-012 Trial

Aug 22, 2024

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

More ›

Articles

Nov 21, 2022

Advancing Our hhc Mission with the Eisai US hhceco Center: Our New State-of-the-Art Headquarters

Author: Ivan Cheung, Chairman & CEO, Eisai Inc. Eisai’s culture is defined by our human health care (hhc) mission, which guides the work we do to help increase the benefits health care provides...

learn more

Fact Sheet

Learn more about key information and milestones.

learn more

Stay up to date with the latest from Eisai with email alerts

Contact Information

For media inquiries, please contact:

Corporate
Patricia Councill
Director, Corporate Communications
551-262-2686
Patricia_Councill@eisai.com

Neurology
Libby Holman
Senior Director, Product Communications
201-753-1945
Libby_Holman@eisai.com

Oncology
Michele Randazzo
Director, Product Communications
201-248-2228
Michele_Randazzo@eisai.com